| Name | Title | Contact Details |
|---|
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.
Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level.
Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive early detection and precision medicine for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.
Transcriptic is a very small company. We like it that way. Our work culture is an unstructured environment where you can do your best work supported by a group of your peers. Everyone sets their own goals, and everyone is empowered to think creatively. We work hard and we focus, but we don`t do all-nighters or heroic pushes. Grinding yourself into the ground is a fast way to introduce bugs. Life science demands precision; we take our time and we get it right. We use commercial-off-the-shelf solutions when they`re available, and we aren`t afraid to open them up to get to more exacting standards—and if we can`t find it, we build it. We`re completely devoted to solving Transcriptic`s challenges as cleverly as possible to build solid, reliable, intelligent solutions.
Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer`s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.